Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid Malignancies

Mitochondrial apoptosis can be effectively targeted in lymphoid malignancies with the FDA-approved B-cell lymphoma 2 (BCL-2) inhibitor venetoclax, but resistance to this agent is emerging. We show that venetoclax resistance in chronic lymphocytic leukemia is associated with complex clonal shifts. To...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Cell
Main Authors: Guièze, Romain, Liu, Vivian M., Rosebrock, Daniel, Jourdain, Alexis A., Hernández-Sánchez, María, Zurita, Aina Martinez, Sun, Jing, Hacken, Elisa Ten, Baranowski, Kaitlyn, Thompson, Philip A., Heo, Jin-Mi, Cartun, Zachary, Aygün, Ozan, Iorgulescu, J. Bryan, Zhang, Wandi, Notarangelo, Giulia, Livitz, Dimitri, Li, Shuqiang, Davids, Matthew S., Biran, Anat, Fernandes, Stacey M., Brown, Jennifer R., Lako, Ana, Ciantra, Zoe B, Lawlor, Matthew A, Keskin, Derin B., Udeshi, Namrata D., Wierda, William G., Livak, Kenneth J, Letai, Anthony G., Neuberg, Donna, Wade Harper, J., Carr, Steven A., Piccioni, Federica, Ott, Christopher J., Leshchiner, Ignaty, Johannessen, Cory M., Doench, John, Mootha, Vamsi K., Getz, Gad, Wu, Catherine J.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6801112/
https://ncbi.nlm.nih.gov/pubmed/31543463
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2019.08.005
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados